Literature DB >> 15104670

Humanized animal models for autoimmune diseases.

J W Gregersen1, S Holmes, L Fugger.   

Abstract

The development of transgenic mice expressing human DR and DQ major histocompatibility complex (MHC) class II molecules has been of value in studying the immunopathology of human MHC class II-associated autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, insulin-dependent diabetes mellitus and celiac disease. Such mice have been used to identify the target antigens that are involved in the initiation of these diseases. Many of the mice develop aspects of the human diseases, either spontaneously or following immunization with the relevant antigen, thus providing an in vivo disease model, which may be used as a tool for further understanding the disease mechanisms and testing novel immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104670     DOI: 10.1111/j.0001-2815.2004.00243.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  10 in total

1.  Human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis.

Authors:  Tobias L Freitag; Candace Cham; Hsiang-Hsuan Sung; Georg F Beilhack; Ivana Durinovic-Belló; Salil D Patel; Roderick T Bronson; Detlef Schuppan; Grete Sønderstrup
Journal:  Gastroenterology       Date:  2010-03-18       Impact factor: 22.682

2.  A model for personalized in vivo analysis of human immune responsiveness.

Authors:  Hannes Kalscheuer; Nichole Danzl; Takashi Onoe; Ted Faust; Robert Winchester; Robin Goland; Ellen Greenberg; Thomas R Spitzer; David G Savage; Hiroyuki Tahara; Goda Choi; Yong-Guang Yang; Megan Sykes
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

3.  CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

Authors:  Katharina N Steinitz; Pauline M van Helden; Brigitte Binder; David C Wraith; Sabine Unterthurner; Corinna Hermann; Maria Schuster; Rafi U Ahmad; Markus Weiller; Christian Lubich; Maurus de la Rosa; Hans Peter Schwarz; Birgit M Reipert
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

Review 4.  An integrated approach to design novel therapeutic interventions for demyelinating disorders.

Authors:  Oscar G Vidaurre; Jia Liu; Jeffery Haines; Juan Sandoval; Richard Nowakowski; Patrizia Casaccia
Journal:  Eur J Neurosci       Date:  2012-06       Impact factor: 3.386

5.  Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens.

Authors:  Chao Jiang; Umesh S Deshmukh; Felicia Gaskin; Harini Bagavant; Julie Hanson; Chella S David; Shu Man Fu
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

6.  Differential induction of experimental autoimmune encephalomyelitis by myelin basic protein molecular mimics in mice humanized for HLA-DR2 and an MBP(85-99)-specific T cell receptor.

Authors:  Maria T Greene; Anne M Ercolini; Mathew DeGutes; Stephen D Miller
Journal:  J Autoimmun       Date:  2008-11-12       Impact factor: 7.094

Review 7.  Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease.

Authors:  Emily M L Chastain; Stephen D Miller
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 8.  Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Authors:  Brad Bolon; Marina Stolina; Caroline King; Scot Middleton; Jill Gasser; Debra Zack; Ulrich Feige
Journal:  J Biomed Biotechnol       Date:  2010-12-28

9.  Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity.

Authors:  Matthias G von Herrath; Gerald T Nepom
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

10.  Rodent models for investigating the dysregulation of immune responses in type 1 diabetes.

Authors:  Feng-Cheng Chou; Heng-Yi Chen; Shyi-Jou Chen; Mei-Cho Fang; Huey-Kang Sytwu
Journal:  J Diabetes Res       Date:  2013-03-11       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.